Bradley J. Stish, MD

Articles by Bradley J. Stish, MD

Managing Oxybutynin-Related Dry Mouth in Prostate Cancer Care

April 4th 2026

Frequent hydration, salivary gland stimulation, and overnight humidifier use are strategies Bradley J. Stish, MD, employs to manage dry mouth.

Bradley J. Stish, MD, emphasized the role of decision-making processes between physicians and patients when deciding between 2.5 and 5 mg of oxybutynin.

Optimizing Oxybutynin Doses for ADT-Induced Hot Flashes in Prostate Cancer

ByBradley J. Stish, MD

April 2nd 2026

Bradley J. Stish, MD, emphasized the role of decision-making processes between physicians and patients when deciding between 2.5 and 5 mg of oxybutynin.

Latest Updated Articles

Managing Oxybutynin-Related Dry Mouth in Prostate Cancer Care
April 4th 2026

Trending on CancerNetwork

FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD

Investigators Initiate Dosing in Phase 1b/2 Trial of SNB-101 in ES-SCLC

Perioperative Durvalumab Plus Enfortumab Vedotin Improves Survival in MIBC

107 Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer (ABC)

108 Long-Term Safety and Efficacy of First-Line Next Generation CDK4-Selective Inhibitor Atirmociclib + Letrozole for the Treatment of Patients With HR+/HER2− Metastatic Breast Cancer